Kornimate/medical-research-clean huggingface dataset:
electronic catheter stethoscope

Conditions: Pelvic Organ Prolapse; Gynecologic Cancers; Uterine Leiomyomata; Adenomyosis; Endometrial Hyperplasia; Other Abnormal Uterine and Vaginal Bleeding; Pelvic Mass; Pelvic Pain

Summary: this is an observational, exploratory study designed to collect (record) and analyze normal and abnormal sound data from the human bladder during surgery using a novel sensor-based catheter system (electronic catheter stethoscope) and to develop algorithms to detect changes of baseline bladder and ureteral function. the electronic catheter stethoscope device will measure acoustic and pressure data within the bladder. the measurements will be used to detect any leakage from the bladder and/or changes in baseline ureteral flow by correlation of sound data with surgical data reported by the surgeon. these data will be used to develop algorithms to detect changes of baseline bladder and ureteral function. the algorithms will be tested in future clinical trials.


Eligibility criteria:
inclusion criteria * age 18 or older * plan to have one of the following types of surgery: * laparoscopic or abdominal gynecological surgery * vaginal surgery * able to provide written informed consent exclusion criteria * under 18 years of age * bilateral tubal ligation as the single reason for surgery * current pregnancy * unable to provide written informed consent
travoprost aps versus xalatan® in patient reported outcomes and ocular surface health

Conditions: Open Angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to understand differences in visual function-related patient-reported outcomes between a non-bak medication (travoprost aps) and a bak-preserved medication (xalatan®) in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * must have a clinical diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component), or ocular hypertension in at least 1 eye. * must be willing and able to discontinue use of any topical ocular medication other than the study medication for the duration of the study. * must have had intraocular pressure (iop) controlled with mono-therapy using xalatan® for at least 1 continuous month prior to visit 1. * women of childbearing potential must meet all of the following conditions at visit 1: * they are not breast-feeding. * they have a negative urine pregnancy test at visit 1. * they agree to undertake a urine pregnancy test upon entering and exiting the study. * they are not planning to become pregnant during the course of the study. * they are currently using, and agree to use adequate birth control methods for the duration of the study. * other protocol-specified inclusion criteria may apply. exclusion criteria: * any abnormality preventing reliable applanation tonometry in the study eye(s). * presence of any ocular pathology in either eye seen during the slit lamp or fundus exams, that in the opinion of the investigator may preclude the safe administration of test article or safe participation in this study. * dry eye or keratoconjunctivitis sicca (kcs) which has been, or is currently being, treated with the use of punctal plugs, punctal cautery, restasis®, or topical ocular corticosteroids. * patients who have undergone keratorefractive ocular laser procedures, corneal surgery or surgery to the corneal surface, including but not limited to lasik and prk, within 6 months prior to visit 1. * patients who have undergone intraocular or extra-ocular surgery, in either eye, within 6 months prior to visit 1. * any history of ocular infections or inflammatory ocular conditions within the past 3 months in either eye. * use of any systemic medications on a chronic basis that have not been on a stable dosing regimen for at least 30 days prior to visit 1. * use of ocular medications other than xalatan® within 7 days of visit 1. * use of corticosteroids within 30 days of visit 1. * use of contact lenses within 30 days of visit 1. concomitant use of contact lenses is also excluded for the duration of the study. * history of intolerance or hypersensitivity to any component of the test articles. * participation in an investigational drug or device study within 30 days of entering this study. * history or evidence of corneal transplant or transplant variant procedures. * other protocol-specified exclusion criteria may apply.

Keywords: open angle glaucoma ocular hypertension oag oh
post-massive weight loss chest contouring: inferior pedicle technique in pseudo-gynecomastia correction

Conditions: Gynecomastia

Summary: the massive weight loss leads an important excess of skin on thoracic level giving the aspect of a feminine breast with a relatively important ptose. several techniques were described in the literature about gynaecomastia , but the post-bariatric pseudo-gynaecomastia was not handled yet enough. moreover, there is no single consensual technique on this subject. the technique used in this service was described for the first time in 2008 ( 1 ) on a serie of 8 patients with an average follow-up of 13 months. although the results are promising, no other publication was done, and the procedure remains badly represented in the world literature.


Eligibility criteria:
inclusion criteria: * inferior pedicle gynaecomastia surgery * age \> 16 exclusion criteria: * age \< 16
rhythmic interlimb coordination in children with developmental coordination disorder

Conditions: Developmental Coordination Disorder

Summary: this study is a case-controlled observational study, involving children with developmental coordination disorder (dcd) and typically developing children with an age from 8 up to 12 years old. the study aims to investigate interlimb coordination of the lower limbs and sensorimotor synchronization ability in children with dcd compared to age-matched typically developing children during gait and fundamental lower limb coordination task to 2 metronomes with different temporal structures. the study consists of a maximum of 4 sessions (2 descriptive sessions, 2 experimental sessions), each lasting around 60 minutes. depending on the preferences of the child and parents, the sessions can be combined in 2 sessions of 2 hours. during the first descriptive session, the participant will perform the m-abc2 test to assess gross and fine motor function. the mbema-s will be used to examine rhythm perception ability. during the second descriptive session, children will perform the kids bestest to examine postural control, and two cognitive tests (digit span, go-no/go test) to assess executive functioning. during the third visit (experimental session), interlimb coordination and synchronization will be investigated during three tasks with different dynamic balance demands (seated, walking and running) in three conditions: in silence, to beats in isochronous metronome (discrete structure), to beats in non-isochronous metronomes (sinusoidal structure). in the last experimental session, the tempi of the auditory metronomes will be set at higher and lower tempi than the preferred comfortable tempo of the child.


Eligibility criteria:
inclusion criteria: * are aged between 8-12 years * have no medical conditions that could impede their motor abilities. * children with a diagnosis of dcd, consistent with the dsm-v (blank et al., 2019), or total percentile score \<p16 on the movement assessment battery for children edition 2 (m-abc-2), will be included in the group of (probably) dcd. * the m-abc score total of typical developing children needs to be ≥p25 for inclusion exclusion criteria: • have other neurological, orthopaedical, cardiorespiratory or intellectual impairment that could affect their motor abilities (verified using a health questionnaire)

Keywords: developmental coordination disorder interlimb coordination gait sensorimotor synchronization metronomes
a pilot trial of adalimumab for the treatment of osteoarthritis

Conditions: Osteoarthritis

Summary: a 12 week trial of adalimumab in subjects with active erosive inflammatory oa who have ahd an inadequate response to nsaid therapy


Eligibility criteria:
inclusion criteria: * age 45 or older, \>/=2 tender and 2 swollen joints, inadequate response to nsaid therapy, hand radiographs with evidence of erosive changes, acceptable form of birth control exclusion criteria: * autoimmune arthropathy, history of psoriasis, previous tnf therapy, current use of any dmard, evidence of tb, history of hep c, b, or hiv

Keywords: osteoarthritis
patient driven recovery with nalmefene and coaching

Conditions: Opioid-use Disorder; Harmful; Use, Alcohol

Summary: in collaboration with the first pavlov state medical university in st. petersburg, russia, we are proposing a pilot, open label, non-randomized clinical trial to evaluate the safety, feasibility, acceptability, and preliminary efficacy of treatment for alcohol and opioid use disorders combining nalmefene and recovery coaching (educational and behaviorally oriented drug counseling). the proposed pilot study will also be used to further develop and refine the recovery coaching/counseling intervention and to train additional cadre of clinicians and researchers in st. petersburg, russia.

the specific aims and hypotheses of the proposed study are as follows: specific aim 1: to evaluate the safety, feasibility, acceptability, and preliminary efficacy of treatment of alcohol and opioid use disorders combining nalmefene and recovery coaching for rehabilitation of detoxified opioid dependent individuals in russia. specific aim 2: to further develop and refine the recovery coaching/counseling intervention and to train additional cadre of clinicians and researchers in st. petersburg, russia.

Eligibility criteria:
inclusion criteria: * individuals who meet dsm iv criteria for opioid dependence, who use street methadone (the main, most frequently used street opioid in saint petersburg, russia) by intravenous injections, who have a history of alcohol use disorder or high risk alcohol use, who successfully completed inpatient, medically supervised detoxification, who are seeking a rehabilitation treatment following detoxification, and who pass a naloxone challenge (indicating the current lack of physiological dependence on opioids) exclusion criteria: * current suicide or homicide risk; current psychotic disorder or major depression; inability to understand the consent form or assessments; pregnancy; acute medical conditions requiring medical treatment, co-occurring dependence/abuse of other drugs including alcohol, benzodiazepines, or amphetamine type stimulants (ats)
implantable cardioverter defibrillator (icd) function during ventricular assist device (vad) implantation

Conditions: Heart Failure

Summary: the purpose of this research study is to test the function of a subjects implantable cardioverter defibrillator (icd) function throughout the duration of their heart surgery. icd function can be altered during some types of heart surgery such as those when a pump (ventricular assist device - vad) is implanted. the investigators would like to study the mechanism of device and icd malfunction.

icd function is typically measured prior to and after surgery. for the study, the investigators will measure icd lead function multiple times throughout the surgery as well, to determine if and when device malfunction occurs. icd lead function is measured noninvasively through a specialized computer the same way it is checked in the clinic. in addition, the investigators will test icd function as they usually do following surgery.

Eligibility criteria:
inclusion criteria: * patients ages 18 and older * have a wireless implantable cardioverter defibrillator (icd) and are undergoing vad implantation or other cardiothoracic surgery. exclusion criteria: * patients who are pacemaker dependent * children, human fetuses, neonates * prisoners will not be included * pregnant women will not be included

Keywords: implantable cardioverter defibrillator ventricular assist device
long-term oxygen treatment (ltot) in chronic obstructive pulmonary disease: factors influencing survival

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this prospective cohort study is to determine factors involved in survival in new copd patients treated by long-term oxygen therapy. background: long-term oxygen therapy is indicated in patients with severe copd. no studies have been performed in the past 20-25 years to examine the results of early clinical trials. further studies are necessary to understand the utility of oxygen therapy in severe copd.

long-term oxygen therapy prolongs life in patients with severe copd and severe resting hypoxemia. the objective of this study is to measure the survival in relation to the level of initial resting hypoxemia, serious co-morbidities, and nutritional status in copd patients treated by long-term oxygen therapy. after enrollment at the beginning of oxygen therapy, following data will be collected during 3 years. lung function, blood gas analysis, exercise capacity measured by the 6-min walk distance test (6-mwd), dyspnea scale, bode index, quality of life, indirect and direct costs will be analyzed every year.

Eligibility criteria:
inclusion criteria: * copd patients on necessity of long-term oxygen therapy * patients treated by ltot, with or without clinically fulfilled criteria for ltot, with pao2\<55mmhg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. patients with pao2 56-59mmhg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56% * patient clinically stable * patient with oxygen device of antadir network * oral and written consent exclusion criteria: * patient with obstructive sleep apnea or overlap syndrome * patient with non invasive ventilation * patient with evolutive cancer. * inability to complete questionnaires * inability to attend outpatient clinic

Keywords: long-term oxygen therapy copd patients on necessity of long-term oxygen therapy
the effect of subclinical leaflet thrombosis and prosthesis type on transcatheter aortic valve degeneration (popular pet tavi)

Conditions: Aortic Valve Stenosis

Summary: a multicentre cross-sectional cohort study to assess the difference in bioprosthetic micro-calcification activity, detected with 18f-naf pet-ct, as early marker of transcatheter valve degeneration, between patients with vs. without subclinical leaflet thrombosis at five years after tavi; and between patients with intra-annular vs. supra-annular tavi prostheses.

subclinical leaflet thrombosis (sclt) occurs frequently after tavi and has been associated with an increased risk of valve dysfunction. a persistent form of sclt may lead to thrombus calcification and valve degeneration and increase the long-term risk of symptomatic bioprosthetic valve deterioration. intra-annular in comparison to supra-annular tavi valves have been associated with a higher risk of sclt and valve thrombosis. intra-annular valves may create larger neo-sinuses and flow stagnation zones, which favour local thrombogenicity. whether different prosthesis types lead to a higher degree of transcatheter valve calcification and degeneration is currently unexplored. recently, 18f-sodium fluoride (18f-naf) positron emission tomography (pet) has emerged as a non-invasive modality capable of imaging bioprosthetic micro-calcification activity, which is an early and powerful predictor of valvular dysfunction and eventually valve failure. in the present study, we investigate for the first time, the differences in quantified bioprosthetic micro-calcification activity with 18f-naf pet as early marker of transcatheter valve degeneration between patients with and without sclt and between patients with intra-annular vs. supra-annular prostheses at five years after tavi.

Eligibility criteria:
inclusion criteria: * successful tavi with sapien or corevalve evolut prosthesis about 5 years ago * able to undergo hybrid 18f-naf pet-ct imaging and transthoracic echocardiography * written informed consent exclusion criteria: * temporary or chronic oral anticoagulation use after tavi * known severe renal insufficiency * known severe paravalvular regurgitation * history of valve-in-valve procedure * history of aortic valve re-intervention (including percutaneous paravalvular leak closure)

Keywords: tavi tavr subclinical leaflet thrombosis bioprosthetic valve deterioration intra-annular supra-annular
study evaluating etanercept and sulphasalazine in ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: the purpose of this study is to compare the efficacy of etanercept and sulphasalazine in the treatment of ankylosing spondylitis.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ankylosing spondylitis * active ankylosing spondylitis exclusion criteria: * complete ankylosis of spine * previous treatment with etanercept

Keywords: ankylosing spondylitis (as)
comparative study between hydrocortisone and mannitol in treatment of postdural puncture headache

Conditions: Headache

Summary: fifty patients of both sex, aged 18-50 years and asa i and ii undergoing elective lower abdominal and pelvic surgery under spinal anesthesia were included in this randomized double-blind study. patients were randomly divided into 2 groups 25 each; group (i) received intravenous hydrocortisone 100mg every 8 hours for 48 hours and group (ii) received intravenous infusion of mannitol 20% 100ml over 30 minutes followed by 100ml every 12hours. mean (+/- sd) of headache intensity at 0, 6, 12, 24 and 48 hours after beginning of treatment was assessed using visual analog scale.


Eligibility criteria:
inclusion criteria: * aged 18-50 years old. * both sex. * asa physical status i and ii. * 70-90 kg body weight. * height 160-180 cm. * elective lower abdominal and pelvic surgery e.g. repair of inguinal hernia, repair of incisional hernia, varicocele and hydrocele. exclusion criteria: * patients with impaired kidney or liver functions. * history of cardiac or central nervous system disease. * uncontrolled medical disease (diabetes mellitus and hypertension) * history of intake of non-steroidal anti-inflammatory drugs or opioids within 24 h before surgery * allergy to the used medications * patient's refusal * duration of surgery more than 120 minutes.
case report of nerve root sleeve reinforcement and reconstruction and sacral canal plasty for the treatment of sacral canal

Conditions: Tarlov Cysts

Summary: a retrospective study of the changes in the vas scores and imaging examinations after the reconstruction and reinforcement of nerve root sleeves and caudal angioplasty for the treatment of sacral cysts from august 2017 to january 2018 was used to evaluate the efficacy of the surgical prescription.

objective: to clarify the curative effect of nerve root sleeve reconstruction and reinforcement and caudal plasty in the treatment of sacral cysts design: a retrospective study of the changes in the vas score and imaging examinations after the reconstruction and reinforcement of nerve root sleeves and sacral canoplasty for the treatment of sacral cysts from august 2017 to january 2018 to evaluate the efficacy of the surgical prescription.

Eligibility criteria:
inclusion criteria:a) symptomatic nerve root cyst diagnosed by mri b) the capsule of the cyst is intact and the sacral lamina is not defective c) no other diseases of the nervous system, pelvic floor and important organs d) reconstruction of patients with artificial dural nerve root sleeve reinforcement - exclusion criteria:a) non-radiotomy cyst or asymptomatic cyst b) the cyst causes severe bone erosion to lamina absorption c) combined with other diseases of the nervous system, pelvic floor and important organs d) those who have not used artificial dura mater for nerve root sleeve reinforcement and reconstruction -

Keywords: tarlov cysts surgery
identification of genes involved in juvenile idiopathic arthritis by wholel exome sequencing

Conditions: Arthritis, Juvenile Rheumatoid

Summary: juvenile idiopathic arthritis (jia) is considered to be a multifactorial disease caused by a combination of environmental factors and predisposing genetic factors. twins studies found a strong heritability (strong genetic factors) but genetic studies such association studies of large cohorts of patient (gwas or genome wide association study) have elucidated less than 20 % of the genetic basis of jia. the vision of the genetics of multifactorial diseases has recently changed revealing a large clinical and genetic heterogeneity of these diseases. indeed, the advent of next-generation sequencing identified non-multifactorial genetic hereditary disease related to mutations in genes having strong effect on the onset of the disease without real impact of environmental factors among the so called "multifactorial diseases" (parkinson's, diabetes, osteoarthritis, alzheimer's, hypertension ...)the investigators propose to study 30 families with several forms of jia by next-generation sequencing. identifying the genetic basis of jia in these families will help to better understand the physiopathology of this disease and may help to the identification of novel therapeutic targets for other patients with jia.


Eligibility criteria:
inclusion criteria: * aji oligoarticular form \<4 joints * aji polyarticular form\> 4 joints * aji forms systemic arthritis * duration for more than six weeks * onset of symptoms before the age of 16 years * or rheumatoid factor or ana + or ccp +acceptation of both parenth to participate to the research and to perfom blood samples for genetic studies exclusion criteria: * the (the) patient (e) is under tutorship or curatorship * the (the) patient (e) is under judicial protection * the (the) patient (e), or his parents, refuses to sign the consent * it is impossible to give (the) patient (e) information lit * jia spondyloarthropathies such * jia type psoriatic arthritis or enthesopathy * jia not classifiable

Keywords: juvenile idiopathic arhtritis jia gene identification whole exome sequencing next generation sequencing identification of molecular basis acceptation of both parents to participate to the study